# Leuprolide (Lupron)

> GnRH agonist used for prostate cancer, endometriosis, and precocious puberty.

Source: https://peptides.cafe/peptide/leuprolide
Category: GnRH Agonist · Hormonal
Tag: FDA-Approved · Oncology

## Mechanism
Synthetic nonapeptide GnRH agonist. Continuous administration desensitizes pituitary GnRH receptors, suppressing LH/FSH and downstream sex hormone production (medical castration).

## Research areas
- Advanced prostate cancer
- Endometriosis
- Uterine fibroids
- Central precocious puberty
- Gender-affirming care

## Common research protocols
- Prostate cancer depot: 7.5 mg IM monthly, or 22.5 mg every 3 months.
- Precocious puberty: Pediatric weight-based depot dosing.

## Study summaries
- "Leuprolide in metastatic prostate cancer" — NEJM (1984): Established equivalence to orchiectomy for androgen suppression.

## Considerations
- FDA-approved.
- Initial testosterone flare; hot flashes, bone density loss with long-term use.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.